Xenon Pharmaceuticals to Participate in Upcoming Investor Conferences
04/25/2022 - 04:01 PM
BURNABY, British Columbia, April 25, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company today announced that Xenon’s management team will participate in the following investor conferences:
Jefferies Biotech on the Bay Summit Date/Location: April 26-27, 2022 in Miami, FL (one-on-one investor meetings only) Bloom Burton & Co. Healthcare Investor Conference 2022 Date/Location: May 2-3, 2022 at the Metro Toronto Convention Centre in Toronto, ON Presentation: Tuesday, May 3, 2022 Time: 11:30 am Eastern Time 2022 RBC Capital Markets Global Healthcare Conference Date/Location: May 17-18, 2022 at the InterContinental Barclay in New York, NY Fireside Chat: Wednesday, May 18, 2022 Time: 11:00 am Eastern Time
Details on company presentations and webcasts can be found on the “Investors” section of Xenon’s website at investor.xenon-pharma.com. When available, webcasts will be posted for replay following the event. The above listed dates and times are subject to change.
About Xenon Pharmaceuticals Inc. Xenon Pharmaceuticals (NASDAQ:XENE) is a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. We are advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy. For more information, please visit www.xenon-pharma.com .
“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.
Investor/Media Contact :investors@xenon-pharma.com
Xenon Pharmaceuticals Inc
XENE Rankings
#3064 Ranked by Stock Gains
XENE Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Pharmaceutical Preparation Manufacturing
Country
Canada
City
Burnaby
About XENE
xenon® (nasdaq: xene) is a biopharmaceutical company focused on the development of novel medicines through the application of our proprietary discovery platform, which we refer to as extreme genetics. our product candidates are based on genetic insights derived from our research of families where individuals exhibit severe traits, or phenotypes. we apply our expertise to predict which phenotypes are caused by single-gene defects. by identifying and characterizing the single-gene defects responsible for such severe phenotypes, we gain valuable insights into their function in human biology and their potential as drug targets. given that these targets are often involved in diseases beyond the rare genetic disorders in which they are first identified, we are developing proprietary product candidates to treat both orphan as well as more prevalent diseases.
